Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.
Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.
复制标题
DOI：
10.2807/1560-7917.es.2021.26.39.2100894
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Investigators, other members of the Working Group for the Study of COVID-19 in Navarre
中科院分区：
文献类型：
--
作者：
Martínez-Baz I;Trobajo-Sanmartín C;Miqueleiz A;Guevara M;Fernández-Huerta M;Burgui C;Casado I;Portillo ME;Navascués A;Ezpeleta C;Castilla J;Working Group for the Study of COVID-19 in Navarre;Investigators, other members of the Working Group for the Study of COVID-19 in Navarre
按产品划分的COVID-19疫苗有效性（两种剂量Comirnaty，Spikevax或Vaxzevria和Janssen之一），抗感染范围为50%至100%。（95% CI：42 - 57），杨森为86% Vaxzevria-Comirnaty联合用药组（70 - 93）; ≥ 60岁患者中，17%（-26至45），杨森为68%（48至80），Spikevax为68%（48至80）;住院率从杨森的74%（43至88）到其他产品的> 90%。两剂疫苗对住院治疗非常有效，但对感染控制不理想。
COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control.